Symbiotec Pharmalab IPO Oversubscribed 71x: Huge Investor Demand

Symbiotec Pharmalab’s Initial Public Offer (IPO) saw massive demand, oversubscribed by an impressive 71.26 times during its bidding period.

Investors placed bids for 93.52 crore shares, significantly exceeding the 1.31 crore shares available for subscription.

IPO Snapshot

• Oversubscription: 71.26 times
• Shares Bid: 93.52 crore
• Shares On Offer: 1.31 crore
• Bidding Period: August 24 to August 27, 2026
• Price Band: Rs 938-988 per share

The IPO consisted of a fresh issue up to Rs 150 crore and an offer for sale (OFS) of up to Rs 1,607 crore.

The OFS was executed by Satwani Holdings LLP, Rosewood Investments, and India Business Excellence Fund III.

Capital Utilization & Anchor Investment

Funds from the fresh issue are earmarked for repaying outstanding borrowings and general corporate purposes.

Prior to the main offering, Symbiotec Pharmalab secured Rs 526.19 crore from anchor investors on August 21, 2026.

Symbiotec Pharmalab operates in the pharmaceutical and biotechnology sector, boasting over three decades of experience.

The company specializes in APIs, CDMO services, and complex injectables, holding a global presence in corticosteroid and steroidal-hormone APIs.

Financial Performance

• Consolidated Net Profit (FY ending March 31, 2026): Rs 109.88 crore
• Sales (FY ending March 31, 2026): Rs 869.15 crore

This overwhelming investor response underscores strong market confidence in Symbiotec Pharmalab’s business model and future prospects.